Literature DB >> 16945323

Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes.

Ana Maria Dueñas-Romero1, Philippe M Loiseau, Michèle Saint-Pierre-Chazalet.   

Abstract

Sitamaquine is an 8-aminoquinoline which is active by the oral route for the treatment of life-threatening visceral leishmaniasis caused by Leishmania donovani, with an IC50 of 29.2 microM against the promastigote form in vitro. At high concentration (100 microM), sitamaquine affected parasite motility, morphology and growth in a way that was only partially reversible. As a first approach to determine its mechanism of action, we describe the interaction of sitamaquine with parasite membrane components, representing the first barrier to be crossed by the drug. Analysis of the physicochemical interactions of sitamaquine with monolayers of phospholipids and sterols at the air-water interface showed that these interactions only occurred in the presence of anionic phospholipids. Thus, electrostatic interactions between positively charged sitamaquine and the negative polar headgroups are a pre-requisite for subsequent hydrophobic interactions between the sitamaquine aromatic ring and the alkyl chains of phospholipids leading to drug insertion into the monolayer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16945323     DOI: 10.1016/j.bbamem.2006.07.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.

Authors:  Roma Sinha; Jayeeta Roychoudhury; Partha Palit; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Role of Lipid Composition in the Interaction and Activity of the Antimicrobial Compound Fengycin with Complex Membrane Models.

Authors:  Elisabeth Mantil; Iryna Buznytska; Grace Daly; Anatoli Ianoul; Tyler J Avis
Journal:  J Membr Biol       Date:  2019-10-14       Impact factor: 1.843

3.  The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase.

Authors:  Luis Carvalho; Juan Román Luque-Ortega; Carmen López-Martín; Santiago Castanys; Luis Rivas; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

4.  Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.

Authors:  Arpita Kulshrestha; Ruchi Singh; Dhiraj Kumar; Narender Singh Negi; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

5.  N'-(4-Bromo-benzyl-idene)quinoline-8-sulfonohydrazide.

Authors:  Kely Navakoski de Oliveira; Ricardo José Nunes; Sabine Foro
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-03-19

6.  Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes.

Authors:  Carmen López-Martín; José María Pérez-Victoria; Luis Carvalho; Santiago Castanys; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2008-09-15       Impact factor: 5.191

7.  Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum.

Authors:  Sílvia Vale-Costa; Nuno Vale; Joana Matos; Ana Tomás; Rui Moreira; Paula Gomes; Maria Salomé Gomes
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

Review 8.  Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance.

Authors:  P M Loiseau; S Cojean; J Schrével
Journal:  Parasite       Date:  2011-05       Impact factor: 3.000

9.  Structures, targets and recent approaches in anti-leishmanial drug discovery and development.

Authors:  Karin Seifert
Journal:  Open Med Chem J       Date:  2011-03-09

Review 10.  The Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates.

Authors:  Philippe M Loiseau; Kaluvu Balaraman; Gillian Barratt; Sébastien Pomel; Rémy Durand; Frédéric Frézard; Bruno Figadère
Journal:  Molecules       Date:  2022-04-02       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.